Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Keeping Track: A Glut Of Big Approvals While Lartruvo Makes Its Market Exit

Keeping Track Feature image

Related Content

Erelzi's Disappearing Indications: Biosimilar Loses Two Of Enbrel's Labeling Claims

Feb 09 2018

GSK Wins First-Ever Voucher Race With Anti-Malarial Approval

Jul 23 2018

GSK’s Malaria Drug Tafenoquine Heads To US FDA Panel Review With Agency Backing

Jul 11 2018

US Biosimilars: FDA Seeks To Build On Record Number Of Approvals, But Shutdown May Blunt Progress

Jan 23 2019

Keeping Track: Xarelto Earns CV Risk Reduction Claim In Quiet Week; Spotlight On Formal Dispute Resolution

Oct 14 2018

Accelerated Approval Withdrawals Through The Years

Apr 25 2019

FDA Bests Annual Novel Drug Approval Record With Four Oks In One Week

Dec 22 2017

Lartruvo Phase III Fail Rocks Lilly Oncology Plans

Jan 21 2019

Keytruda/Inlyta Data Stoke Competition In Kidney Cancer

Feb 12 2019

Lilly’s Lartruvo Withdrawal Stirs Questions About Payment For Accelerated Approval Drugs

Apr 26 2019

Benlysta Is Niche, But Growing, So GSK's Not Giving Up On Lupus

Aug 07 2017

Related Companies

AbbVie Inc.

Samsung Bioepis Co., Ltd.

Amgen, Inc.

GSK plc

Eli Lilly and Company

Johnson & Johnson

Novartis AG

Novartis AG

Bausch Health Companies Inc.

Medicines for Malaria Venture

Merck & Co., Inc.

Pfizer Inc.

Merck KGaA

Additional Topics

United States Drug Review Regulation BioPharmaceutical

More from Product Reviews

More from Pink Sheet

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window